Document Detail

Neuroprotective Therapy Using Granulocyte-Colony Stimulating Factor for Patients With Worsening Symptoms of Thoracic Myelopathy: A Multicenter Prospective Controlled Trial.
MedLine Citation:
PMID:  22652593     Owner:  NLM     Status:  Publisher    
ABSTRACT: Study Design. An open-labeled multicenter prospective controlled clinical trial.Objective. To confirm the feasibility of granulocyte colony-stimulating factor (G-CSF) administration for patients with thoracic myelopathy.Summary of Background Data. Although G-CSF is best known as an important cytokine commonly used to treat neutropenia, it also has non-hematopoietic functions. Previous experimental studies have shown that G-CSF can enhance tissue regeneration of several organs, such as the heart and brain. We previously reported that G-CSF promotes functional recovery after spinal cord injury in rodents. Based on those findings, we started a clinical trial of neuroprotective therapy using G-CSF for patients with worsening symptoms of thoracic myelopathy.Methods. Patients whose Japanese Orthopaedic Association (JOA) score for thoracic myelopathy had decreased two points or more during a recent one-month period were eligible for entry. After giving informed consent, patients were assigned to G-CSF and control groups. The G-CSF group (n = 10) received G-CSF 10 μg/kg/day intravenously for five consecutive days. The control group (n = 14) received similar treatments as the G-CSF group except for G-CSF administration. The primary outcome was JOA recovery rate at one month after G-CSF administration or initial treatment.Results. There was greater improvement in neurologic functioning between baseline and one month follow-up in the G-CSF group (JOA recovery rate: 29.1 ± 20.5%) compared with the control group (JOA recovery rate: 1.1 ± 4.2%) (P < 0.01). No serious adverse events occurred during or after the G-CSF administration.Conclusion. The results provide evidence that G-CSF administration caused neurological recovery in patients with worsening symptoms of thoracic compression myelopathy.
Tsuyoshi Sakuma; Masashi Yamazaki; Akihiko Okawa; Hiroshi Takahashi; Kei Kato; Mitsuhiro Hashimoto; Koichi Hayashi; Takeo Furuya; Takayuki Fujiyoshi; Junko Kawabe; Chikato Mannoji; Tomohiro Miyashita; Ryo Kadota; Yukio Someya; Osamu Ikeda; Tomonori Yamauchi; Masayuki Hashimoto; Toshimi Aizawa; Atsushi Ono; Shiro Imagama; Tokumi Kanemura; Hideki Hanaoka; Kazuhisa Takahashi; Masao Koda
Related Documents :
10552143 - Prognostic value of pressure-flow study in surgical treatment of benign prostatic obstr...
15062183 - Late urinary function after prostate brachytherapy.
3397743 - The bipolar endoprosthesis in avascular necrosis of the femoral head.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-30
Journal Detail:
Title:  Spine     Volume:  -     ISSN:  1528-1159     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-6-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7610646     Medline TA:  Spine (Phila Pa 1976)     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Spine Section, Department of Orthopaedic Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan, *Department of Orthopaedic Surgery, Tohoku University School of Medicine † Department of Orthopaedic Surgery, Hirosaki University Graduate School of Medicine ‡ Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine § Spine Center, Konan Kosei Hospital ¶ Department of Clinical Research, Chiba University Hospital.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Autophagic cell death exists.
Next Document:  Differences Between TNF-alpha Receptors Type 1 and Type 2 in the Modulation of Spinal Glial Cell Act...